Structure Therapeutics Inc.
GPCR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001888886
No open-market purchases or sales by Structure Therapeutics Inc. insiders were filed in the last 90 days; 192 institutions reported holding it in 13F filings for Q2 2026, worth $3.62B in total; no superinvestor holds it.
Key figures
- Market capADS ratio not in SEC data
- –
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −5 vs. previous quarter
- 192
- 13F valueReported value at the end of Q2 2026
- $3.62B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$141.2M
- No comparable prior period
- Free cash flow, FY2025
- -$225.8M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 5.93M
- Shares sold short
- Change
- −1.22M
- −17.1% vs. previous
- Days to cover
- 6.50
- At average daily volume
Superinvestors holding GPCR, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding GPCR at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Structure Therapeutics Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 22, 2026 (view filing)5:59 PM ET | Sep 21 | 1 day | Coll Crespo BlasCHIEF MEDICAL OFFICER | SSale | −12.0K | $36.15 | −$434.6K | –1.16K after | Derivative10b5-1 |
| Sep 2, 2026 (view filing)9:18 PM ET | Sep 1 | 1 day | Lin XichenCHIEF SCIENTIFIC OFFICER | SSale | −5.94K | $46.92 | −$278.7K | –0 after | Derivative3 lots10b5-1 |
| Aug 19, 2026 (view filing)8:23 PM ET | Aug 18 | 1 day | Lin XichenCHIEF SCIENTIFIC OFFICER | SSale | −11.8K | $17.82 | −$210.6K | –0 after | Derivative3 lots10b5-1 |
| Aug 5, 2026 (view filing)4:49 PM ET | Aug 4 | 1 day | Lin XichenCHIEF SCIENTIFIC OFFICER | SSale | −11.8K | $16.48 | −$194.8K | –0 after | Derivative2 lots10b5-1 |
| Jul 24, 2026 (view filing)9:11 AM ET | Jul 22 | 2 days | FMR LLC10% Owner, Other: See Remark 1 | SSale | −52.4K | $16.69 | −$873.8K | –16.1K after | Derivative2 lots |
| Jul 15, 2026 (view filing)6:57 PM ET | Jul 14 | 1 day | Lin XichenCHIEF SCIENTIFIC OFFICER | SSale | −23.6K | $16.99 | −$401.6K | –0 after | Derivative2 lots10b5-1 |
| Jun 29, 2026 (view filing)8:32 PM ET | Jun 25 | 4 days | Lin XichenCHIEF SCIENTIFIC OFFICER | SSale | −23.6K | $16.36 | −$386.6K | –0 after | Derivative10b5-1 |
| Apr 16, 2026 (view filing) | Apr 14 | 2 days | FMR LLC10% Owner, Other: See Remark 1 | SSale | −52.4K | $18.36 | −$961.1K | –32.2K after | Derivative2 lots |
| Jan 20, 2026 (view filing) | Jan 15 | 5 days | FMR LLC10% Owner, Other: See Remark 1 | SSale | −52.4K | $27.77 | −$1.45M | –48.3K after | Derivative8 lots |
| Dec 10, 2025 (view filing) | Dec 8 | 2 days | FMR LLC10% Owner, Other: See Remark 1 | SSale | −157.1K | $23.99 | −$3.77M | –0 after | Derivative10 lots |
Top 10 13F holders, Q2 2026
See all 192 holdersThe largest institutional positions in Structure Therapeutics Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 7,810,306 | $419.2M | 0.02% | −593,143−7.1% | Reduced |
| Wellington Management Group LLP | 7,379,433 | $396.1M | 0.07% | +119,146+1.6% | Added |
| Avoro Capital Advisors LLC | 6,555,555 | $351.8M | 3.16% | 00.0% | Unchanged |
| Jupiter Topco LLC | 5,204,212 | $279.3M | 0.11% | +5,204,212 | New |
| Deep Track Capital, LP | 4,740,072 | $254.4M | 3.75% | +460,224+10.8% | Added |
| BVF Inc | 3,366,823 | $180.7M | 4.62% | −92,535−2.7% | Reduced |
| Morgan Stanley | 2,806,640 | $150.6M | 0.01% | +501,183+21.7% | Added |
| OrbiMed Advisors LLC | 2,209,400 | $118.6M | 2.25% | +733,997+49.7% | Added |
| Principal Financial Group Inc | 1,752,753 | $94.1M | 0.05% | −1,011−0.1% | Reduced |
| American Century Companies Inc | 1,682,179 | $90.3M | 0.04% | +244,148+17.0% | Added |
Holders of 5% or more of GPCR
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Structure Therapeutics Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 15.00%32.1M shares | +1.80 ppfrom 13.20% | Feb 10, 20238 filings | Nov 5, 2026 | SEC |
| Wellington Management Group LLP | 13G/A | 10.10%21.4M shares | −1.80 ppfrom 11.90% | Feb 6, 20247 filings | Feb 10, 2026 | SEC |
| Avoro Capital Advisors LLC | 13G | 9.38%16.2M shares | – | Feb 14, 20243 filings | Nov 14, 2025 | SEC |
| Janus Henderson Group PLC | 13G/A | 7.70%4.45M shares | −0.30 ppfrom 8.00% | Nov 14, 20245 filings | Nov 14, 2025 | SEC |
| Deep Track Capital, LP | 13G/A | 5.95%12.3M shares | −1.37 ppfrom 7.32% | Feb 3, 20237 filings | Feb 13, 2026 | SEC |
Politician trades
All politician trades in GPCR1 member of Congress reported 1 trade in Structure Therapeutics Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Nov 2, 2023 |  Thomas R. Carper Senate · DE | Sell (full) | $1K-$15K |
Senate · DE · Nov 2, 2023
Sell (full)$1K-$15K